Tigecycline: a new glycylcycline antimicrobial agent (Q28247555)

American Journal of Health-System Pharmacy

Europe PubMed Central

title

Tigecycline: a new glycylcycline antimicrobial agent (English)

0 references

author name string

Nishaminy Kasbekar

series ordinal

1

0 references

language of work or name

English

0 references

publication date

1 July 2006

0 references

published in

0 references

volume

63

0 references

issue

13

0 references

page(s)

1235-43

0 references

cites work

Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Ribosomal protection proteins and their mechanism of tetracycline resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

In vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibil

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

In vitro activities of tigecycline against the Bacteroides fragilis group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

In vitro activity of tigecycline against Bacteroides species

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Tigecycline: what is it, and where should it be used?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050487